好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Guillain-Barre Syndrome As An Emerging Side Effect of SARS-CoV-2 Vaccination: A Literature Review
Autoimmune Neurology
P1 - Poster Session 1 (9:00 AM-5:00 PM)
050

Our review aims to study the significance of the association between the manifestations of Guillain-Barre syndrome (GBS) and COVID-19 immunization, as well as provide medical practitioners with relevant clinical information through a detailed summary of the current cases of GBS related to the COVID-19 vaccines. Additionally, we will shed light on the impact of associated demographic risk factors such as age, gender, and comorbid conditions in the development of GBS post-vaccination.

 

Guillain-Barre syndrome (GBS) is a rare and potentially fatal post-infectious, immune-mediated neuropathy characterized by rapidly progressive weakness and ascending paralysis. As an adverse reaction to the COVID-19 vaccines, GBS is becoming an arising catastrophe increasingly reported as a complication of the COVID-19 vaccines.

 

A literature search was conducted across four databases: PubMed, PubMed Central, Medline (through PubMed), and Google Scholar using predefined keywords. These keywords included “Guillain Barre Syndrome,” “COVID-19 vaccination”, “COVID-19”. The search criteria were set to filter cases of GBS in post-COVID-19 vaccination, reported between March 2020 to October 2021.

A total of eighteen articles were selected from peer-reviewed journals which documented twenty-eight patients (ages ranged between 20-82 years old) that had developed GBS after receiving COVID-19 vaccinations; fifteen males and thirteen females. GBS side effects were reported with five COVID-19 vaccines including Pfizer, Moderna, Janssen, AstraZeneca (now called Vaxzevria), and a vector-based vaccine. In addition, the average duration between COVID-19 vaccine administration and GBS symptoms onset was noted to be 12.46 days. 

Although it is too early to draw conclusions concerning GBS following COVID-19 vaccination, we recommend monitoring for cases suggestive of GBS following vaccination and implementing post-vaccination surveillance to ensure adequate data gathering of this outcome, as well as to determine its cause. Additionally, we encourage even further large-scale research into this area.

Authors/Disclosures
Nasrin Jahan, MBBS
PRESENTER
Dr. Jahan has nothing to disclose.
Maha Hameed (AlFaisal University) Ms. Hameed has nothing to disclose.
Surya Suresh, MBBS Dr. Suresh has nothing to disclose.
Harshadayani Jagadish Kumar, MBBS (UAB Pediatric Neurology) Dr. Jagadish Kumar has nothing to disclose.
No disclosure on file
No disclosure on file